AlphaRose Therapeutics was started by Casey McPherson, a critically acclaimed musician from Austin, Texas, when his daughter Rose was diagnosed with a rare genetic disease with no cure. McPherson spent years putting a team and science together to change the broken healthcare system for children like his daughter. AlphaRose is a new business and technology model, changing the way we develop and commercialize genetic medicines. Starting with their Antisense Oligonucleotide platform, and children with severe neurological diseases, AlphaRose plans on rapidly developing hundreds of genetic treatments for small population diseases at scale. The companies' lead product, "Rosiphersen" is slated for clinic in early 2026, and has a large pipeline of additional assets.